CS220271B1 - Substituted aryloxypropanolamines,salts thereof and method of producing same - Google Patents
Substituted aryloxypropanolamines,salts thereof and method of producing same Download PDFInfo
- Publication number
- CS220271B1 CS220271B1 CS617681A CS617681A CS220271B1 CS 220271 B1 CS220271 B1 CS 220271B1 CS 617681 A CS617681 A CS 617681A CS 617681 A CS617681 A CS 617681A CS 220271 B1 CS220271 B1 CS 220271B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- formula
- carbon atoms
- ether
- hydroxy
- propoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 5
- 150000003839 salts Chemical class 0.000 title abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- 229910052759 nickel Inorganic materials 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 25
- -1 hydrioibromide Chemical compound 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 11
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 4
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229960002704 metipranolol Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- LDLDYFCCDKENPD-UHFFFAOYSA-N ethenylcyclohexane Chemical compound C=CC1CCCCC1 LDLDYFCCDKENPD-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Vynález sa týká substituovaných aryloxypropanolamínov obecného vzorca I OH OCH^HCH^NHR2 \Q^-NHCOOR (l‘)> kde R1 je alkyl aleho/a alkloxylalkyl s. 2 až 5 atómami uhlíka, piriamy alebo rozvětvený alkenyl si 2i až 5 atémami uhlíka aleho/a eyteloalkyl· s 3 až 6 atómami· uhlíka a® je rozvětvený alkyl s 3 až 4 atómami uhlíka a/ /aleblo cykloailkyl s 3 až 6 atómami uhlíka a ich siolí. Tieto nlové látky sú významné účinné betalytika, použitelná pri léčbě róznych oběhových porúch. Vynález tiež chrání niekolko spósobov výroby látok obecného vzorca I.The present invention relates to substituted aryloxypropanolamines of formula (I) OH OCH 2 HCH 2 NHR 2 Q1 -NHCOOR (l ‘)> where R 1 is alkyl and / or alkyloxyalkyl 2 to 5 carbon atoms, piriam, or branched alkenyl is 2 to 5 carbon atoms and / or eyteloalkyl · with 3 to 6 carbon atoms; branched alkyl having 3 to 4 carbon atoms and / cycloalkyl having 3 to 6 carbon atoms and their salt. These nickel substances are significant effective betalytics, useful in the treatment of rhinitis circulatory disorders. The invention also protects several ways of producing the general substances of formula I.
Description
Vynález sa týká substituovaných arylo xypropanOlamínov všeobecného vzorca IThe present invention relates to substituted aryloxypropanol amines of formula I
O-CHrCH-CH^NHfíSputum-O-CH NHfí
nhcoor (I) kdenhcoor (I) where
R1 je priamy alebo rozvětvený alkyl alfetto alkoxyalkyl s 1 až 5 atómami uhlíka, priamy alebo rozvětvený alkenyl a 2 až 5 atómami uhlíka alebo cykloalkyl s 3 až 6 atómami uhlíka aR 1 is a straight or branched (C 1 -C 5) alkyl or alkoxyalkyl, straight or branched (C 2 -C 5) alkenyl or (C 3 -C 6) cycloalkyl; and
R2 je rozvětvený alkyl s 3 až 4 atómami uhlíka alebo cykloalkyl s 3 až 6 atómami uhlíka.R 2 is a branched alkyl of 3 to 4 carbon atoms or cycloalkyl of 3 to 6 carbon atoms.
Vynález sa týkia tiež solí substituovaných aryloxypropanolamínov všeobecného vzorca I, ako i spóšohov, ktorými možno uvedené látky připravovat.The invention also relates to salts of the substituted aryloxypropanolamines of the formula I as well as to the spohoses with which they can be prepared.
Substituované aryloxypropanolamíny všeobecného vzorca I sú nové, v literatúre dioposial nepopísané zlůčeniny, ktoré vykazujú typické účinky betalytlk, podobné akio je tfoi u aryloxyprppanolamínov iným špósobom substituovaných (čs. pat. spis č. 128 471, americký pat, spis. č. 3 468 376, NSR pat. splS. č. 1 236 523, švajcarsky pat. spis. č. 451114 a 453 363). Všetky študované látky vykazujú antiizOprenailínovú, antiarytmickú a lokálně anestetickú aktivitu a účinky na tracheálny síval. Látky s pracovným označením BL-445 (příklad 31) a BL-443 (příklad 30) sú fairtoakiolioglcky ekvivalentně klinicky používanému metipranololu [1- (2,3,5-trimethyl-4-ace|toxyf enoxy) -3-izopropylamino-2-propanolu], taktiež možno předpokládat ich aplikáciu při terapii róznych porúch funkci® srdca a krvného oběhu. Účinnost látok padla vynálezu je uvedená v tabulke 1 — 3.Substituted aryloxypropanolamines of formula I are novel dioposial compounds not described in the literature which exhibit the typical effects of betalytes, similar to those of aryloxyproppanolamines substituted in other ways (U.S. Pat. No. 128,471, U.S. Pat. No. 3,468,376). , German Patent Application No. 1 236 523, Swiss Patent Nos. 451114 and 453 363). All study compounds exhibit antiisprenailin, antiarrhythmic and local anesthetic activity and effects on tracheal muscle. The substances designated BL-445 (Example 31) and BL-443 (Example 30) are fairlyakiologically equivalent to clinically used metipranolol [1- (2,3,5-trimethyl-4-acetoxyphenoxy) -3-isopropylamino-2 -propanol], may also be expected to be of use in the treatment of various cardiac and circulatory disorders. The efficacy of the compounds of the invention is shown in Table 1-3.
Substituované aryloxyprapandlaraíny všeobecného vzorca I je možné pódia vynálezu připravit róznymi spóSobmi, napr. tak, že sa nechá reagovatThe substituted aryloxyprapandlarains of the formula I can be prepared according to the invention in various ways, e.g. by reacting
a) zlúčenina všeobecného vzorca IIa) a compound of formula II
OHOH
II
O-CH^CH-CH-Ci (^-nhcoor4 (!/) márnym amíniom všeobecného vzorca NH2R2, v ktorom R2 znamená to isté ako· vo vzorciO-CH 2 CH-CH-C 1 (N 4 -hcoor 4 (1H)) amine of formula NH 2 R 2 , wherein R 2 is the same as in the formula
I.I.
b) zlúčenina všeobecného vzorca IIIb) a compound of formula III
R1 znamená to isté akio vo vZorci I, s primárným amínom všeobecného vzorca NH2R2, v ktoriom R2 znamená to isté ako vo· vzorci I,R 1 is the same as in Formula I, with the primary amine of formula NH 2 R 2 , wherein R 2 is the same as in Formula I,
c) zlúčehina všeobecného vzorca IVc) a compound of formula IV
OH [04-NHCOOR4 v ktoromOH [04-NHCOOR 4] wherein
R1 znamená to isté ako vo vzorci I s 1-alkylaminoi-2,3-epoxypriOpániom všeobecného· vzorca VR 1 is the same as in formula I with 1-alkylaminoalkyl-2,3-epoxypriOpániom of formula V ·
CH.— CH-CH.-NHR \\Z ° IV) v ktoromCH - CH - CH - NHR (IV) in which
R2 znamená to isté ako vo vzorci I, d) zlúčenina všeobecného vzorca IV v ktorom R2 is the same as in formula I, d) a compound of formula IV wherein
R1 znamená ta isté ako vo vzorci I, s 1 -alkylamino- 3-chlór-2-prOpanolbin všeobecného vzorca VIR 1 is the same as in formula I, with 1 alkylamino- 3-chloro-2-prOpanolbin formula VI
OHOH
II
Cl—CH2—CH—CH2—NHR2 (VI), v ktoriom v ktoromCl-CH2-CH-CH2-NHR2 (VI) in which
R1 znamená to isté akio vo vzorci I, s priR2 znamená to isté ako vo vzorci I.R 1 is the same as in formula I, with R 2 is the same as in formula I.
Pri přípravě podlá vynálezu prebieha re£20271 akcia medzi obidvotma východzími zložkami v prostředí alkoholu, alebo· Vody za katalytického posioibenla hydroxidu alkalického· kovu, například hydroxidu sodného,, huď při teplote miestnosti, alebo prii teplote bodu, varu reakčnej zmesy.In the preparation according to the invention, the reaction proceeds between the two starting components in an alcoholic medium or with a catalytic posioiben of an alkali metal hydroxide, for example sodium hydroxide, at room temperature or at the boiling point of the reaction mixture.
Po skončení reakcie sa reakčná zmes najčastejšie spracuje tak, že sa pretrepe zriedeným roztokom hydroxidu·, alkalického kovu, organické nazpúšťadlo oddestiluje: a odparek predstavujúci surový bazický ester sa přečistí převedením na sol', alkalizáciOu a extrakciiou do organického s vodou nemiešateťnéhio rloizpúš ťadla;After completion of the reaction, the reaction mixture is most often worked up by shaking it with a dilute alkali metal hydroxide solution, distilling off the organic solvent, and purifying the crude base ester residue by conversion to salt, alkalization and extraction into an organic water-immiscible solvent.
Z tohoto roztoku je možné bázický ester previesf pniamio na žiadanú slof a tú dalej čistit kryštailzáciou z vody,, organického rozpúšťadla, alebo zo zmesy organických rozpúšťadiel. Zo solí- s anorganickými· kyselinami vhodnými; pre přípravu aplikačných foriem prichádzajú v úvahu: hydrochliorid, hydrioibromid, síran, fosforečnan, připadne zo stolí s organickými kyselinami napr. šťavelan, vínan, maleinát, funiarát a iné.From this solution, the basic ester can be converted into the desired slurry and further purified by crystallization from water, an organic solvent, or a mixture of organic solvents. Of salts with inorganic acids suitable; suitable for the preparation of dosage forms are: hydrochloride, hydrioibromide, sulphate, phosphate, optionally from tables with organic acids e.g. oxalate, tartrate, maleate, funiarate and others.
Podrobnosti· přípravy sú uvedené v nasledujúcich príkladoch prevedenia.Preparation details are given in the following examples.
P r í k 1 a· d 1Example 1 and 1
Etyl-4 [ (2-hydroxy-3-cyklohexylamino)-propoxy ] karbanilátEthyl 4 - [(2-hydroxy-3-cyclohexylamino) -propoxy] carbanilate
K roztoku 10,5 g (0,038 mol] etyl-4[ (2-hydroxy-3-chlór ) -propoxy J-karbanilátu v 50 ml metanolu sa přidá 4,9 g (0,05 mol) cyklohexylamínu a zahrieva sa 10 h v autokláve pri tepliote 110 °C.To a solution of 10.5 g (0.038 mol) of ethyl 4 - [(2-hydroxy-3-chloro) -propoxy] -carbanilate in 50 ml of methanol is added 4.9 g (0.05 mol) of cyclohexylamine and heated for 10 h. autoclave at 110 ° C.
Po vychladnutí reakčnej zmesy sa· vakuová oddestiluje metanol a cyktobexylamín, odparek rozpustí v zriedenej kyselině chloroVodíkovej, pretrepe třikrát éterlom a z oddelenej vodnej fázy sa alkalizáciOu uvolní báza,, ktorá sas vytrepe doi éteru. Po vysušení bezvodým síranom horečnatým sa a filtrátu přidáním; éterického. roztoku suchého chlorovodíka vylúči hydrochlorid,, ktorý sa prekryštalizuje zto zmesy 2-propantol-éter (t. t. 156. až 159 °G.After cooling the reaction mixture, methanol and cyctobexylamine are distilled off in vacuo, the residue is dissolved in dilute hydrochloric acid, shaken three times with ether and the base is freed from the separated aqueous phase and shaken into ether. After drying over anhydrous magnesium sulfate, and the filtrate added; ethereal. of hydrochloric acid, which is recrystallized from 2-propantol-ether (m.p. 156-159 ° C).
Příklad 2Example 2
Propyl-2[ (2-hydroxy-3-izOpropylamino·)-pr opoxy ] kar bani látPropyl 2 - [(2-hydroxy-3-isopropylamino) -propoxy] carboxylic acid
K roztoku 9,0 g (0,035 mol)· propyl-2( (2,,3-epoxy)-propoxy] karbanilátu v 30 ml 2-propanolu sa přidá 3,5 g (0,06 mol) iztoprtopylamínu a 2 ml; viody; Reakčná zmes sa zahrieva v autokláve pri teplote 100 °G 5 hi Po vychladnutí reakčnej: zmesy sa vákuovo oddestiluje rozpúšťadlo a přebytek izopropylamínu. Odparek sia· rozpustí v zriedenej kyselině chlorovodíkové], pretrepe třikrát éíberom a z oddelenej Vodnej fáze alkalizáciOu uvolní báza, ktorá sa vytrepe do·· éteru. Po vysušení bezvodým síranom horečnatým sa· z filtrátu přidáním.; éterického; roztoku suchého chlertevodíka, vylúči, hydrachltarid,,, ktorý sa prekryštalujp· zo· zmesy acetón-éter (t. 1.115 až 118 °C).To a solution of 9.0 g (0.035 mol) of propyl 2 ((2,3-epoxy) propoxy) carbanilate in 30 ml of 2-propanol is added 3.5 g (0.06 mol) of istoprtopylamine and 2 ml; The reaction mixture is heated in an autoclave at 100 ° C for 5 hours. After cooling the reaction mixture, the solvent and excess isopropylamine are distilled off in vacuo, dissolved in dilute hydrochloric acid], shaken three times with ether and freeed from the aqueous phase After drying over anhydrous magnesium sulfate, the filtrate is added by adding an ethereal solution of dry hydrogen chloride, precipitating, the hydrachltaride, which is recrystallized from acetone-ether (m.p. 1.115-118 ° C). .
Příklad 3Example 3
Izopropyl-3.[, (;2-hydr,Qxy‘-3-tere.butylamin|Oo)-propoxy ] karbaniilátIsopropyl 3 - [, (; 2-hydr , Qxy'-3-tert-butylamine | 10o) -propoxy] carbaniilate
12,4 g; (0,064 moll) izopropylestoru kyseliny 3-hydtaxykarhanitovej. a 8,3; g, (0,064 mol) 14erc.butylaminoi-2,3-epO'xypmpánu·. v 40 ml Vody a v 2 ml 42% roztoku hydrtoixidu sodného; sa mieša 6 h pri tepliote miestniosti., Giny· roztek sa. zLeje. a živičná zsaženina rozpustí; v zriedenej, kyselme, chlorovodíkovej, pnetcepe· tbikráts éterom a z oddelenej vodnej fáze alkalizáciOu uvolní báza, ktorá sa vytrepe do éteru. Po vysušení bezviodým.! sinaném horečnatým: z: filtrátu přidáním éterického. roztoku suchého chlorovodíka sa. vylúči hydrochlorid,, ktorý. sa prekryštalizuje zo· zmesy acetón-etanol (t. t. 136 — 138 °C).12.4 g ; (0.064 mol) of 3-hydtaxycarhanitic acid isopropyl ester. and 8.3; g, (0.064 mol) 14-tert-butylamino-2,3-epo-xypmpane. in 40 ml of water and in 2 ml of 42% sodium hydrtoixide solution; is stirred for 6 h at room temperature., Giny · spread. bad. and dissolving the bituminous precipitate; in dilute, acidic, hydrochloric, methyl ether with ether and from the separated aqueous phase the alkalization liberates the base, which is shaken into ether. After drying dry. magnesium sulfate: z: filtrate by addition of ethereal. solution of dry hydrogen chloride. the hydrochloride, which. is recrystallized from acetone-ethanol (mp 136-138 ° C).
P r í k 1 a di 4Example 1 and di 4
Cyklohexyl-4:[i (2-hydroxy-3-izopropylamino) -propoxy ] karbanilátCyclohexyl-4: [i (2-hydroxy-3-isopropylamino) -propoxy] carbanilate
5,6 g (QjQ23t mol), cyklohexyleetenu kyseliny 4Ayddo|xykaribamÍavej',, 4$ g (0,023 mol) hydrochlloridu l-chlór-3-izopBopy<lamino-2-prtopanolu a 2,1 g hydroxidu sodného (0,054 mleli), v, 75> mi. etanolu sa zahrieva v zatavenej; trubici IQ h< pri teplote.· 1QQ °C. Z reakčnej zmesy sa« vákuovo, oddestiluje rozpúšťadlo· a zbytek sa suspenduje v 30. ml. 2N hydroxidu Sodného. Uvolněná báza sa vytrepe do éteru, a po vysušení bezvodým síranom horečnatým; ste z filtrátu přidáním éterického raatoto suchého· chlorovodíka vylúči hydrochlorid, ktorý sa prekryštalizuje Zoi zmesy acetón-éter (t. t. 151 až 153 °CJ.5.6 g (Q2O23t mol), 4Ayddroxycaribamic acid cyclohexylethene, 4.00 g (0.023 mol) of 1-chloro-3-isopropanol-2-propanol, hydrochloride and 2.1 g of sodium hydroxide (0.054 ml), at, 75> mi. ethanol is heated in a sealed; tube IQ h < 1 ° C. The solvent is distilled off under vacuum, and the residue is suspended in 30 ml. 2N sodium hydroxide. The liberated base was shaken into ether and dried over anhydrous magnesium sulfate; the hydrochloride is precipitated from the filtrate by addition of ethereal dry hydrogen chloride, which is recrystallized from acetone-ether mixtures (m.p. 151-153 ° C).
S použitím hone popísaných metod, holi připravené· tieto· nové látky (v zátvoirkách pracovné označenie·},:Using the methods described above, the following new substances have been prepared (in working brackets:
1. metyl-2[ (2-hydroxy-3-izopropylamino· )-prioipQxyjkarbaniláthydrochlorid,1. Methyl 2 - [(2-hydroxy-3-isopropylamino) - propioxy] carbanilate hydrochloride;
t. t. 125 až· 127-°G (acetémetanol);t. t. 125 DEG -127 DEG C. (acetemethanol);
(BL-123),(BL-123),
2. metyl-2[ (;2-hydrloxy-3-terc.butylamino)-pnotpoxyjkarbaniláthydEOGhltorid',2. Methyl 2 - [(2-hydrloxy-3-t-butylamino) -pentypoxy] -carbanilateHEOGltoride;
t. t. 99 až 1S£°G (acefióu), (BJi-125-j:,t. t. 99-160 ° C (acephio), (BJi-125-j :,
3. metyl-3[ (2-hydrtoxy-3-izopnopylamiao:·);-prlopoxy ] karbaniláthydr ochlorid,3. methyl-3 - [(2-hydroxy-3-isopnopylamino); - prlopoxy] carbanilate hydride chloride;
1.1. lil· až 112; °C; (aceton?.). (^-133),,1.1. lil · to 112; C; (Acetone ?.). (^ -133) ,,
4. metyl-3[ (2-rhydaí0xy.--3!-terc.butylaminoi)-propoxy ] karbaniláthydr ochlorid,.4. Methyl 3 - [(2-hydroxyphenyl) -3-tert-butylamino] propoxy] carbanilate hydride chloride.
t. t, 163 až 167 °C (2i-pnopanol) (LB-135),t. t, 163-167 ° C (2β-propanol) (LB-135),
5. metyl-4[ (2-hydr|oxy-3-izopropylammo)-prioipoxy ] karbaniláthydr ochlor id,5. Methyl 4 - [(2-hydroxyoxy-3-isopropylamino) -prioipoxy] carbanilate hydrochloride;
1.1. 160 až 163 °C (2-priopaniol-éter) BL-143),1.1. 160-163 ° C (2-propanol-ether) BL-143),
6. metyl-4[ (2-hydroxy-3-terc.butylamino)-prιopoxy]kaιrbaniláthydrochl©rid,6. Methyl 4 - [(2-hydroxy-3-tert-butylamino) propoxy] carbanilate hydrochloride;
1.1.156 až 158 °C (acetón-éter) (BL-145),1.1.156 to 158 ° C (acetone-ether) (BL-145),
7. etyl-2i[: (2-hydrloxy-3-izopropylamino ) -priopoxy ] karbaniláthydrochítorid,7. Ethyl-2i [ : (2-hydrloxy-3-isopropylamino) -propoxy] carbanilate hydrochloride;
1.1.102 až 104 °C (acetón-petrolétier) (BL-223),1.1.102 to 104 ° C (acetone-petroleum ether) (BL-223),
8. etyl-2[ (2-hydr|oxy-3-terc.buty lamino ]-propoxy ] karbanlláthydroohlorid,8. Ethyl 2 - [(2-hydroxyoxy-3-tert-butylamino) -propoxy] carbanl-ethylhydro chloride,
1.1. 128 až 130 °C (acetón-éter) (BL-225),1.1. 128-130 ° C (acetone-ether) (BL-225),
9. etyl-3[ (2-hydhoxy-3-izopropylamino)-pnopoxy ] karbaniláthydrochílorid,9. Ethyl 3 - [(2-hydroxy-3-isopropylamino) -popoxy] carbanilate hydrochloride;
t.1. 104 až 105 °C (acetón-éter) (BL-233),T.1. 104-105 ° C (acetone-ether) (BL-233),
10. etyl-3[ (2-hydroxy-3-terc.butylamino)-priopoxy ] kartíaniláthydrochllorid,10. Ethyl 3 - [(2-hydroxy-3-tert-butylamino) -propoxy] -cartanilate hydrochloride,
t. t. 130 až 131 °C (etanol-éter) (BL-235),t. t. 130-131 ° C (ethanol-ether) (BL-235),
11. etyl-4[ (2-hydroxy-3-izoprlopylaminio)-priopoxy ] karbanlláthydr ochlorid,11. Ethyl 4 - [(2-hydroxy-3-isoprlopylaminio) -propoxy] carbanl-ethyl chloride,
1.1. 141 až 142: QC (2-propanol-éterj (BL-243),1.1. 141-142: Q C (2-propanol-éterj (BL-243),
12. etyl-4[ (2-hydroxy-3-terc.butylamino)-propoxy ] kar bianiláthydrochlorid, t, t. 86 až 88 °C (acetón-éter ) (BL-245),12. Ethyl 4 - [(2-hydroxy-3-t-butylamino) -propoxy] -carbianilate hydrochloride, m.p. 86-88 ° C (acetone-ether) (BL-245),
13. propyl-2[ (2-hydrioxy-3-izopropylamin©)-prlopoxy ] karbianiláthydrochlorid,13. Propyl 2 - [(2-hydrioxy-3-isopropylamine) - propoxy] carbianilate hydrochloride;
1.1. 115 až 118 °C (acetón-éter)1.1. 115-118 ° C (acetone-ether)
BL-323),BL-323),
14. propyl-2i[ (2-hydroxy-3-terc.butyliamino)-priopoxy ] karhaniláthydrochlorid,14. propyl-2i [(2-hydroxy-3-tert-butylamino) -propoxy] carhanilate hydrochloride,
t. it. 123 až 131 °C (acetón-éter) (BL-325),t. it. 123-131 ° C (acetone-ether) (BL-325),
15. propyl-3[ (2-hydrioxy-3-iZopropylamin©)-pnopoxy ] karhaniláthydrochlorid,15. Propyl 3 - [(2-Hydroxy-3-isopropylamino) -popoxy] carhanilate hydrochloride
1.1. 94 až 95 °C (acetón-éter) (BL-333),1.1. 94-95 ° C (acetone-ether) (BL-333),
16. pnopyl-3[ (2-hydrioxy-3-terc,butylamino )-priopoxy ] karibaniláthydrochlorid,16. 3-propyl [(2-hydroxyri-3-tert-butylamino) -propoxy] caribanilate hydrochloride;
1.1. 153 až 155 °C (acetón-éter) (BL-335),1.1. 153-155 ° C (acetone-ether) (BL-335),
17. propyl-4[ (2-hydroxy-3-izapropylamin|o)-prlopoxy ] karbaniláthydrochlorid,17. propyl 4 - [(2-hydroxy-3-isapropylamine | o) - propoxy] carbanilate hydrochloride,
1.1. 140 až 141 °C (acetón-éter) (BL-343),1.1. 140-141 ° C (acetone-ether) (BL-343),
18. propyl-4[ (2-hydnoxy-3-terc.butylamlnio)-prtopioxy ] karhaniláthydrochlorid,18. propyl 4 - [(2-hydroxy-3-tert-butylamino) -propopioxy] carhanilate hydrochloride,
t. t. 76 až 77 °C acetón-éter ) (BL-345),t. t. 76-77 ° C acetone-ether) (BL-345),
19. izopr opyl-2 ((2i-hydroxy-3-izopropylamino) -pnoploxy] karibaniláthydrochlorid,19. Isopropyl-2 ((2i-hydroxy-3-isopropylamino) -popoploxy] caribanilate hydrochloride)
1.1. 111 až 113 °C (acetón) (BL-323izoi),1.1. 111-113 ° C (acetone) (BL-323izo),
20. iziopriopyl-2[ (2-hydroxy-3-terc.butylaminoi) -propoxy ] karbaniláthydrlochlorid,20. Isiopropyl-2 - [(2-hydroxy-3-tert-butylamino) propoxy] carbanilate hydrlochloride;
1.1. 154 až 157 °C (acetón-éter) (BL-izo325),1.1. 154-157 ° C (acetone-ether) (BL-iso325),
21. izopr©pyl-2|[ (2-hydroxy-3-izobutylamiln©) -prlapoxyjkar bianiláthydrochlorid,21. Isopropyl-2 | [(2-hydroxy-3-isobutylamino) -propoxycarbianilate hydrochloride,
1.1. 149 až 152 °C (acetón-éter) (BL-izo324),1.1. 149-152 ° C (acetone-ether) (BL-iso324),
22. izOpropyl-3[ (2-hydrOxy-3-iZopropylamino) -pnopoxy ] karblaniiáthydrochliorid,22. Isopropyl-3 - [(2-hydroxy-3-isopropylamino) -popoxy] carblaniate hydrochloride,
1.1. 108 až 110°C (acetón-éter) (BL-izo333),1.1. 108-110 ° C (acetone-ether) (BL-iso333),
23. izopropyl-3[ (a-hydnoxy-3-terc.butylamlnot)-propoxy ] karbaniláthydnochlorid,23. Isopropyl 3 - [(α-hydroxy-3-tert-butylamino) -propoxy] carbanilate hydrochloride;
t. t. 136 až 138 °C (acetón-etanol] (BL-izo335),t. t. 136 DEG-138 DEG C. (acetone-ethanol) (BL-iso335),
24. izoipr©pyl-4[ (2-hydrloxy-3-izlopr©pylamino ) -priopoxy ] karbaniláthydrochílorid,24. Isopropyl 4 - [(2-hydrloxy-3-isopropylamino) -propoxy] carbanilate hydrochloride,
t. t. 137 až 139 °C (acetón) (BL-ÍZ0343),t. t. 137-139 ° C (acetone) (BL-Z0343),
25. izopropyl-4[ (2-hydnoxy-3-terc.butylamimo·) -propoxy] karbaniláthydrochílorid,25. Isopropyl 4 - [(2-hydroxy-3-tert-butylamino) propoxy] carbanilate hydrochloride,
t. t. 98 až 100 °C (acetón) (BL-izo345),t. t. 98-100 ° C (acetone) (BL-iso345),
26. butyl-2 [ ( 2rhydroxy-3-iz©priOpylamino)-prlopioxy ] kiařfaaniláthydr ochlorid,26. Butyl 2 - [(2-hydroxy-3-isopropylpylamino) -propioxy] potassium phthalate hydride chloride
t. t. 101 až 102 °C (acetón) (BL-423),t. t. 101-102 ° C (acetone) (BL-423),
27. butyl-2[ (2-hydirioxy-3-.terc.butylaminoi)-prlopoxy ] karblaniiáthydrochliorid,27. Butyl 2 - [(2-hydroxy-3-tert-butylamino) -propoxy] carblaniate hydrochloride,
t. t. 138 až 140 °C (acetón-éter) (BL-425),t. t. 138-140 ° C (acetone-ether) (BL-425),
28. butyl-3[ (2-,hydirιoxy-3-izιopropylamino)-pnopoxy] karbaniláthydr ochlorid,28. Butyl 3 [(2- , hydroxyoxy-3-isopropylamino) -popoxy] carbanilate hydride chloride
t. t. 107 až 109 °C (acetón-éter) (BL-433),t. t. 107-109 ° C (acetone-ether) (BL-433),
29. butyl-3[!(2-hydrOxy-3-terc.butylamino)-phopoxy ] karbaniláthy drochlor id,29. Butyl 3 - [(2-hydroxy-3-tert-butylamino) -phopoxy] carbanilate hydrochloride;
t. t. 140 až 144 °C (acetón-éter) (BL-435),t. t. 140-144 ° C (acetone-ether) (BL-435),
30. butyl-4[ (2-hydroxy-3-.izopropylamin©)-prlopoxy ] karbianiláthydrochlorid,30. Butyl 4 - [(2-hydroxy-3-isopropylamine) - propoxy] carbianilate hydrochloride;
t. t. 124 až 126°C (acetón-éter) (BL-443),t. t. 124-126 ° C (acetone-ether) (BL-443),
31. butyl-4[i(i2rhydroxy-3-terc.bntylamino)-priopioxy ] karbaní 1'áthy drochlorid,31. Butyl-4 - [(1-hydroxy-3-tert-butylamino) -propioxy] -carbanyl hydrochloride;
1.1. 150 až 155 °C (2-propanOl-éterj (BL-445),1.1. 150-155 ° C (2-propanol-ether) (BL-445),
32. pentenyl-2[ (2-hydroxy-3-iZopropylamino )-propoxy ] karhaniláthydroehlorid,32. Pentenyl 2 - [(2-hydroxy-3-isopropylamino) -propoxy] carhanilate hydrochloride;
t.1. 123 až 125 °C (acetón-etaniolj (BL-523),T.1. 123 DEG-125 DEG C. (acetone-ethanol) (BL-523)
33. pentyl-2(<( 2-hydr.oxy-3-terc.butylaininio)-propoxy ] kar bamiláthydr ochlorid,33. Pentyl-2 (<(2-hydroxyoxy-3-tert-butylaininio) propoxy] carboxylate hydride chloride
t. t. 148 až 150 °C (aceton) (BL-525),t. t. 148-150 ° C (acetone) (BL-525),
34. pentyl-3[ (2-hydroxy-3-izopropylaminoj-propoxy ] karbaniláthydrochíorid,34. Pentyl 3 - [(2-hydroxy-3-isopropylamino-propoxy) carbanilate hydrochloride,
1.1. 118 až 120 °C (acetón-éter) (BL-533),1.1. 118-120 ° C (acetone-ether) (BL-533),
35. pentyl-3[ (2-hydrloxy-3-terc.butylamino)-propoxy ] karbaniláthydrochíorid,35. Pentyl 3 - [(2-hydrloxy-3-t-butylamino) -propoxy] carbanilate hydrochloride,
t. t. 135 až 138 °C (acetón-éter) (BL-535),t. t. 135-138 ° C (acetone-ether) (BL-535),
36. penty 1-4 [ (2-hydroXy-3-izopr opy lamino)-propoxy ] karbaniláthydrochíorid,36. penty 1-4 [(2-hydroxy-3-isopropylamino) -propoxy] carbanilate hydrochloride,
1.t. 136 až 138 °C (acetón-petroléter) (BL-543),1.t. 136-138 ° C (acetone-petroleum ether) (BL-543),
37. pentyl-4[ (2-hydroxy-3-terc.butylam.inoj- propoxy ] karbaniláthydrochíorid,37. pentyl 4 - [(2-hydroxy-3-tert-butylamino) propoxy] carbanilate hydrochloride,
1.1. 145 až 147°C (aceton-petrpléfer) (BL-545),1.1. 145-147 ° C (acetone-petroleum ether) (BL-545),
38. cyklohexyl-2[ (2-hydnoxy-3-iaopropylamimo)-propoxy ] karbíaniláthydriochlorid,38. cyclohexyl 2 - [(2-hydroxy-3-iaopropylamimo) -propoxy] carbanilate hydrochloride,
1.1. 147 až 150 °C (2-propanol-éter j (BL-623),1.1. 147-150 ° C (2-propanol-ether j (BL-623)),
39. cyklohexyl-2í[ (2-hydrioxy-3-terc.butylamino) -pnopotxy JkarbaniTáthydnochliorid,39. cyclohexyl-2H - [(2-hydrioxy-3-tert-butylamino) -popopoxy] carbamate hydrochloride,
t. t. 192 až 195 °C (etanol-éter) (BL-625),t. t. 192-195 ° C (ethanol-ether) (BL-625),
40. cykltoihexyl-3[ (i2!-hydroxy-3-izioprlapylamino) -propoxy) karbaniláthydrochíorid,40. cycltohexyl 3 - [(1,2-hydroxy-3-isopropylamino) -propoxy) carbanilate hydrochloride,
1.1. 128 až 129 qC (acetón-éter) (BL-633),1.1. 128 to 129 q C (acetone-ether) (BL-633),
41. cyklohexyl-3[ (2-hydroxy-3-terc.butylamino) -prlopoxy ] karbaniiláthydroichlorid, t. t. 138 až 140 aC (acetón-petroléter) (BL-635),41. Cyclohexyl 3 - [(2-hydroxy-3-t-butylamino) -propoxy] carbaniilate hydroichloride, mp 138-140 and C (acetone-petroleum ether) (BL-635),
42. cyktohexyl-4[ (2-hydroxy-34zopropylamino) -propoxy ] karbaniláthydrochíorid, t. t. 151 až 153 °C (acetón-éter) (BL-643),42. Cychexyl 4 - [(2-hydroxy-34-isopropylamino) -propoxy] carbanilate hydrochloride, m.p. t. 151-153 ° C (acetone-ether) (BL-643),
43. etoxyetyl-2[ (2-hydroxy-3-izoprlopylamino) -propoxy ] karbaniláthydrochíorid, t. it. 102 až 105 °C (acetón-éter) (BL-723),43. Ethoxyethyl 2 - [(2-hydroxy-3-isoprlopylamino) propoxy] carbanilate hydrochloride, i. it. 102-105 ° C (acetone-ether) (BL-723),
44. ettoxyetyl-2[ (2-hydroxy-3-terc.butylamino) -propioxy ] karbaniláthydrochíorid,44. ettoxyethyl 2 - [(2-hydroxy-3-tert-butylamino) -propioxy] carbanilate hydrochloride,
1.1. 133 al 135 “C (2-propanol-éter) (BL-725),1.1. 133 and 135 ° C (2-propanol-ether) (BL-725),
45. etoxyetyl-3[ (2-hydroxy-3-izopropylamimo) -propioxy ] karbaniláthydrochíorid,45. ethoxyethyl 3 - [(2-hydroxy-3-isopropylamimo) -propioxy] carbanilate hydrochloride,
1.1. 147 až 150 °C (metanol-éter) (BL-733),1.1. 147-150 ° C (methanol-ether) (BL-733),
46. etOxyetyl-3[ (2-hydnoxy-3-terc.butylamimo) -propioxy ] karbanilátfumarát, t. t. 143 al 146 °C (etanol-éter) (BL-735),46. Ethoxyethyl 3 - [(2-hydroxy-3-tert-butylamimo) -propioxy] carbanilate fumarate, m.p. t. 143 and 146 ° C (ethanol-ether) (BL-735),
47. et'Oxyetyl-3 [ (2-hydroxy-3-izobutylamino) -propoxy ] karbaniláthydrochíorid,47. et'Oxyethyl 3 - [(2-hydroxy-3-isobutylamino) propoxy] carbanilate hydrochloride,
t. t. 124 al 126 °C (acetón-éter ) (BL-734),t. t. 124 and 126 ° C (acetone-ether) (BL-734),
48. etoxyetyl-4[ (2-hydroxy-3-izopropylaminio) -propoxy ] karbanilátfumarát,48. ethoxyethyl 4 - [(2-hydroxy-3-isopropylamino) propoxy] carbanilate fumarate;
1.1. 175'al 178 °C (metanol-éter) (BL-743),1.1. 175 ° C and 178 ° C (methanol-ether) (BL-743),
49. etoxye:tyl-4[ (2-hydr oxy-3-terc.butylamíno>) -pr oploxy ] karbanilátfumarát, t. t. 177 až 179 °C (metanol-éter) (BL-745),49. ethoxyethyl 4 - [(2-hydroxy-3-tert-butylamino) -proploxy] carbanilate fumarate, m.p. t. 177-179 ° C (methanol-ether) (BL-745),
50. etoxyetyl-4[ (2-hydroxy-3-izobutyla.mino j -propoxy ] karbaniláthydrochíorid,50. ethoxyethyl 4 - [(2-hydroxy-3-isobutylamino) propoxy] carbanilate hydrochloride,
1.1. 158 al 160 °C (acetén-etanolj (BL-744),1.1. 158 and 160 ° C (acetene-ethanol) (BL-744),
51. etoxyetyl-2[ (2-hydroxy-3-iziobutylaminioj -prlopoxy] karbanilátioxalát,51. ethoxyethyl 2 - [(2-hydroxy-3-isobutylamino) propoxy] carbanilate dioxalate;
t. t. 138 až 143 °C (etanol-éter) (BL-724),t. t. 138-143 ° C (ethanol-ether) (BL-724),
52. alyl-2[ (2-hydroxy-3-izobutylaminioj- propoxy ] karbamiláthydr ochlorid, . t. t. 119 až 121 °C (acetón-petroléter) (BL-323),52. allyl-2 [(2-hydroxy-3-isobutylamino-propoxy) carbamilate hydride, mp 119-121 ° C (acetone-petroleum ether) (BL-323),
53. alyl-2[ (2-hydroxy-34erc..butylamino)-propoxy ] karbaniláthydrochíorid,53. allyl-2 [(2-hydroxy-34-tert-butylamino) -propoxy] carbanilate hydrochloride,
t. t. 166 až 168 °C (2-propanol-éterj (BL-325)t. t. 166-168 ° C (2-propanol-ether) (BL-325)
54. etyl-4 [ 2-hydr oxy-3-cyklopropylaminio) -propoxy ] karbaniláthydrochíorid,54. Ethyl 4- [2-hydroxy-3-cyclopropylaminio) -propoxy] carbanilate hydrochloride,
t. t. 156 až 160 °C (acetón-etaniolj (BL-246),t. t. 156-160 ° C (acetone ethanol (BL-246)),
55. etyl-4[ (2-hy droxy-3-cyklopenty lamino)-propoxy ] karhaniláthydroehlorid,55. Ethyl 4 - [(2-hydroxy-3-cyclopentylamino) -propoxy] carhanilate hydrochloride,
t. t. 152 až 155 °C (2-propanol-éter) (BL-248),t. t. 152-155 ° C (2-propanol-ether) (BL-248),
56. etyl-2[ (2-hydrioxy-3-cyklohexylamlnoj-propoxy] kar hanlláthydrochlior id,56. Ethyl 2 - [(2-hydrioxy-3-cyclohexylamino-propoxy) -carbonyl] -hydrochrochloride;
t. t. 156 až 159 °C (2-propanol-éterj (BL-249),t. t. 156-159 ° C (2-propanol-ether) (BL-249),
57. etyl-3[ (2-hydrtoxy-3-cyklobexylamlnoj-propoxy ] kar banlláthydr ochllorid, 't. t. 157 až 160 °C (2-propanol-éterj (BL-239),57. Ethyl 3 - [(2-hydrtoxy-3-cyclobexylaminobutyl-propoxy) -carbonyl allyl chloride, m.p. 157-160 ° C (2-propanol-ether) (BL-239);
2'2ΌΖ'7Γ2'2ΌΖ'7Γ
TTabuh-řfeai 1TTabuh-rfeai 1
Efekt testovaných. látok a metípranololu. v kane. 10 mg/20 mb na. Izoprenalínom indukovaná tachykardiu na izolované predsiene morčiat.Effect of tested. substances and metipranolol. in the canoe. 10 mg / 20 mb per. Isoprenaline-induced tachycardia on isolated guinea pig atria.
Látka % zníženia TF po láitke % redukcle pozitivně chrionotr.The% TF reduction after the% reductioncle positive chrionotr.
úč. IP' po» lWbke vzhíádfom Ife kontrol, hodtiotám·acc. IP 'lwbke on Ife controls, values ·
Tabulka1 2.Table 1 2.
Ochranný efekt- látok a metípranololu v· dávke 1 mg . kg-1 i; v: vyjadrenef spotřebouakonitinu pri indukcii arytmii, fibrilácii a letálnej zástavy srdca u anestezovanýcfr morčiat.Protective effect of 1 mg of metipranolol. kg -1 i; v: expressed as aconitine consumption in the induction of arrhythmia, fibrillation, and lethal cardiac arrest in anesthetized guinea pigs.
T a b u 1' k a 3T and b at 1 'k and 3
Akútna toxicita látok po s. c. aplikácii 1% roztoku myšiam.Acute toxicity of substances after s. c. application of 1% solution to mice.
Látka LDso (Mg. kg-1]Substance LD 50 (Mg. Kg -1 )
Lokálně anestetická aktivitaLocal anesthetic activity
Látkasubstance
Index účinnosti LDso/mg .kg-1 povrchová anestézía infiltračná anestéziaEffectiveness index LD 50 / mg .kg -1 surface anesthesia and infiltration anesthesia
2,02.0
1,0 <11.0 <1
1,01.0
2,22.2
1,01.0
4,04.0
7,07.0
4,44.4
4,24.2
1,0 <11.0 <1
7.7 =57.7 = 5
4,2 =24.2 = 2
3,63.6
5.85.8
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS617681A CS220271B1 (en) | 1981-08-18 | 1981-08-18 | Substituted aryloxypropanolamines,salts thereof and method of producing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS617681A CS220271B1 (en) | 1981-08-18 | 1981-08-18 | Substituted aryloxypropanolamines,salts thereof and method of producing same |
Publications (1)
Publication Number | Publication Date |
---|---|
CS220271B1 true CS220271B1 (en) | 1983-03-25 |
Family
ID=5408191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS617681A CS220271B1 (en) | 1981-08-18 | 1981-08-18 | Substituted aryloxypropanolamines,salts thereof and method of producing same |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS220271B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0302694A3 (en) * | 1987-08-05 | 1989-08-02 | Slovenska Akademia Vied | Substituted aryloxyamino-propanols and methods of preparing same |
-
1981
- 1981-08-18 CS CS617681A patent/CS220271B1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0302694A3 (en) * | 1987-08-05 | 1989-08-02 | Slovenska Akademia Vied | Substituted aryloxyamino-propanols and methods of preparing same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0178874B1 (en) | Alkylsulfonamidophenylalkylamines | |
US3152173A (en) | Basically substituted diphenyl-methane derivatives and process for preparing them | |
EP0004011B1 (en) | Phenoxyalkylcarboxylic-acid derivatives, process for their preparation and medicaments containing them | |
US2722529A (en) | Amides of certain l-amevoalkyl-x-phenyl | |
US4018830A (en) | Phenylthioaralkylamines | |
DE2503222A1 (en) | PROCESS FOR THE PREPARATION OF 1-ARYL-OXY-3-N-SUBSTITUTED AMINOPROPAN DERIVATIVES | |
US4055665A (en) | Treating arrythmia with phenylthioaralkylamines | |
CS220271B1 (en) | Substituted aryloxypropanolamines,salts thereof and method of producing same | |
US3077470A (en) | 3-[4-hydroxy-3-(aminomethyl)-phenyl]-4-(4-oxyphenyl)-alkanes and alkenes | |
SU957768A3 (en) | Process for producing piperidine derivatives of esters of 4,5-dialkyl-3-oxy-pyrrol-2-carboxylic acid or their physiologically compatible acid salts | |
US3432549A (en) | Pharmacologically active new substituted benzamides | |
US4259334A (en) | Piperazines and therapeutic utility | |
SU786883A3 (en) | Method of preparing (omega-aminoalkoxy)-bibenzyls or their salts | |
US5055490A (en) | Stereoisomers of benzonitrile derivatives, useful as cardiac arrhythmiac agents | |
US2914552A (en) | 2-diloweralkylamino-alkoxy-3-methyl-benzoic acid esters | |
GB2051796A (en) | (3 - alkylamino - 2 - hydroxypropoxy)-furan - 2 - carboxylic acid anilides and physiologically tolerated acid addition salts thereof processes for their preparation and medicaments containing them | |
JPS58170747A (en) | 2-aminomethyl-6-sulfamoylphenol derivative | |
US3917679A (en) | Quaternary ammonium salts of N-dialkylaminoalkyl-N-(2-indanyl)anilines | |
US2339914A (en) | Chemical compound | |
GB2098599A (en) | N-(2,6-disubstituted phenyl)-alkanediamines | |
US2586850A (en) | 2-isopropylmethylaminopropyl ester of phenylcyclohexenylacetic acid and salts thereof | |
US2576970A (en) | 3-(methylpyrrolidyl-1)propyl para(delta 2)-cyclohexenyloxybenzoates and salts thereof | |
US2584131A (en) | Pyrrolidyl thiolesters | |
US2619499A (en) | Aminoalkyl esters of alpha,alpha-diaryl-gamma,delta-unsaturated aliphatic acids and the production thereof | |
SU869557A3 (en) | Method of preparing 4-(h-hexadecylamino)-benzoic acid or its salts |